J&J rose nearly 3% in morning trading after posting its financial results.
J&J reported Q4 adjusted EPS of $2.67, topping the consensus estimates of $2.59 per share. Sales in the fourth quarter came in at $23.43 billion, missing the consensus projection of $23.66 billion.
Revenue from coronavirus vaccine sales totaled $457 million in the period, well below the analyst estimates of $784.7 million. The company generated $12.87 billion in pharmaceutical sales, short of the estimated $13.52 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments